Format

Send to

Choose Destination
Nucleic Acids Res. 2017 Jan 4;45(D1):D985-D994. doi: 10.1093/nar/gkw1055. Epub 2016 Nov 29.

Open Targets: a platform for therapeutic target identification and validation.

Author information

1
Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK gautier.x.koscielny@gsk.com.
2
GSK, Medicines Research Center, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
3
Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
4
Biogen, Cambridge, MA 02142, USA.
5
European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
6
Wellcome Trust Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SA, UK.
7
National Center for Protein Research, No. 38, Life Science Park Road, Changping District, 102206 Beijing, China.
8
Open Targets, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK dunham@ebi.ac.uk.

Abstract

We have designed and developed a data integration and visualization platform that provides evidence about the association of known and potential drug targets with diseases. The platform is designed to support identification and prioritization of biological targets for follow-up. Each drug target is linked to a disease using integrated genome-wide data from a broad range of data sources. The platform provides either a target-centric workflow to identify diseases that may be associated with a specific target, or a disease-centric workflow to identify targets that may be associated with a specific disease. Users can easily transition between these target- and disease-centric workflows. The Open Targets Validation Platform is accessible at https://www.targetvalidation.org.

PMID:
27899665
PMCID:
PMC5210543
DOI:
10.1093/nar/gkw1055
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center